reports
Moody's Ratings upgrades Cheniere Energy Partners, L.P. to Baa2; outlo...
Moody's Ratings (Moody's) has assigned Baa2 rating to Cheniere Energy Partners, L.P.'s ("CQP") new senior unsecured notes and upgraded the existing senior unsecured notes to Baa2 from Ba1 and changed the outlook to stable from positive. Concurrently, Moody's withdrawn CQP's Ba1 Corporate Family Rati...
- Wedbush Research
GEO GEO GROUP INC. (THE)
LOGN LOGITECH INTERNATIONAL S.A.
WAL WESTERN ALLIANCE BANCORP
SBUX STARBUCKS CORPORATION
RHP RYMAN HOSPITALITY PROPERTIES INC.
PEB PEBBLEBROOK HOTEL TRUST
GPRO GOPRO INC. CLASS A
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
EXLS EXLSERVICE HOLDINGS INC.
EWBC EAST WEST BANCORP INC.
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
OSTK OVERSTOCK.COM INC.
HST HOST HOTELS & RESORTS INC.
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
PK PARK HOTELS & RESORTS INC.
CELH CELSIUS HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
HEAR TURTLE BEACH CORP.
PRPL PURPLE INNOVATION
ARVN ARVINAS HOLDING
LYFT LYFT
GOSS GOSSAMER BIO
RVLV REVOLVE GROUP
IDYA IDEAYA BIOSCIENCES
CRSR CORSAIR GAMING
REAL REALCO
UPST UPSTART HOLDINGS
TWKS THOUGHTWORKS HOLDING
MQ MARQETA INC
JANX JANUX THERAPEUTICS INC
YOU CLEAR SECURE INC
VIGL VIGIL NEUROSCIENCE INC
HR HEALTHCARE TRUST OF AMERICA INC.
BROS DUTCH BROS INC
- Ritika Das
- Robert Driscoll
- Sam Ravina
National Research Corporation Announces First Quarter Results
LINCOLN, Neb.--(BUSINESS WIRE)-- National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024. CEO Commentary Michael Hays, Chief Executive Officer, commented: “NRC continues to be strongly positioned for growth in our expanding markets. Our decades of benchmarks and trusted thought leadership afford healthcare insights unavailable to most competitors, while our client service remains unmatched, and we continue to roll out innovative new products and technologies. Our mission to enhance outcomes and experiences for everyone in the healthcar...
CytomX Therapeutics Announces Clinical Collaboration with Merck to Eva...
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) - CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in patients with advanced metastatic solid tumors including melanoma, renal cell carcinoma and head and neck squamous cell carcinoma - SOUTH SAN FRANCISCO, Calif...
Merus gibt Annahme und vorrangige Prüfung des Lizenzantrags für das Bi...
Merus gibt Annahme und vorrangige Prüfung des Lizenzantrags für das Biologikum Zeno zur Behandlung von NRG1+ NSCLC und PDAC durch die US-Zulassungsbehörde FDA bekannt Nach der Zulassung wird Zeno die erste zielgerichtete Therapie für NRG1+ Krebs sein UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute bekanntgegeben, dass die US-Zula...
Merus annonce l’acceptation par la FDA américaine et l’examen priorita...
Merus annonce l’acceptation par la FDA américaine et l’examen prioritaire de la demande de licence de produit biologique relative à Zeno dans le traitement du CPNPC et de l’ACP NRG1+ S’il est approuvé, Zeno sera le premier traitement ciblé pour le cancer NRG1+ UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 07 mai 2024 (GLOBE NEWSWIRE) -- (Nasdaq : Merus (Merus, la Société, nous ou notre/nos), une société d’oncologie au stade clinique développant des anticorps multispécifiques de pleine longueur innovants (Biclonics® et Triclonics®), a annoncé, ce jour, que la Food and Drug Administrat...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Major Risk-On Developments; Bullish Outlook Intact Over the past two weeks we have discussed the possibility that further downside was limited (4/23/24 Compass) and the mounting evidence that suggests the lows may be in for this pullback (4/30/24 Compass). Major risk-on developments for the broad equity market have continued to roll in over the past week, which we discuss below. As a result, we continue to believe the lows are in for this pullback, and we see the pullback to the 100-day MA on t...
EME EMCOR GROUP
GBX GREENBRIER COMPANIES INC.
BKD BROOKDALE SENIOR LIVING INC.
TRN TRINITY INDUSTRIES INC.
MTZ MASTEC INC.
MATX MATSON INC.
ENSG ENSIGN GROUP INC.
ASC ARDMORE SHIPPING
GNK GENCO SHIPPING & TRADING LTD.
LCM COSTAMARE INC.
SBLK STAR BULK CARRIERS CORP.
GATX GATX CORPORATION
KBR KBR INC.
KEX KIRBY CORPORATION
RAIL FREIGHTCAR AMERICA INC.
WAB WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORPORATION
FSTR L.B. FOSTER CO.
NMM NAVIOS MARITIME PARTNERS
GSL GLOBAL SHIP LEASE INC. CLASS A
DAC DANAOS
EGLE EAGLE BULK SHIPPING
NHC NHC COMMUNICATIONS
J INC.
JACOBS SOLUTIONS INC.
- Valens Research
PBF - Valens Credit Report - 2024 04 22
Credit markets are overstating credit risk with a YTW of 6.853% relative to an Intrinsic YTW of 6.083% and an Intrinsic CDS of 139bps. Meanwhile, credit markets are materially overstating the firm's fundamental credit risk, with its Ba3 credit rating five notches lower than Valens' IG4+ (Baa1) credit rating. Incentives Dictate Behavior™ analysis highlights mixed signals for credit holders. As a positive, management members are material owners of PBF equity relative to their annual compensation,...
Ring Energy Announces First Quarter 2024 Results, Provides Second Quar...
Ring Energy Announces First Quarter 2024 Results, Provides Second Quarter 2024 Outlook and Reiterates Full Year 2024 Guidance ~ Crude Oil and Boe Sales Volumes Exceed High End of Q1 Guidance ~~ LOE per Boe and Capital Spending Below Low End of Q1 Guidance ~ THE WOODLANDS, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today reported operational and financial results for the first quarter of 2024. Also, the Company provided an outlook for the second quarter of 2024 and reiterated its operational and financial guidance for the full ...
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics L...
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application...
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Aileron Therapeutics to Present at Two Upcoming Investor Conferences AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Citizens JMP Life Sciences ConferenceDate: Monday, May 13, 2024Time: 12:00 p.m. EDTFormat: Company presentation H.C....
Aileron Therapeutics Announces Closing of Underwritten Registered Dire...
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announ...
Gritstone bio to Report First Quarter 2024 Financial Results and Provi...
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024 -- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm...
- Valens Research
Aileron Therapeutics Announces Pricing of Underwritten Registered Dire...
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonar...
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phas...
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect Positive trend was observed in seven of eight IPF biomarkers evaluated Low-dose LTI-03 was well-tolerated, with no safety signal observed Data from Cohort 2 evaluatin...
CytomX Therapeutics to Report First Quarter 2024 Results and Provide a...
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 - CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th- SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results a...
- Wedbush Research
LOGN LOGITECH INTERNATIONAL S.A.
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SBUX STARBUCKS CORPORATION
RWT REDWOOD TRUST INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PCRX PACIRA BIOSCIENCES INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MCD MCDONALD'S CORPORATION
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
FATE FATE THERAPEUTICS INC
EXLS EXLSERVICE HOLDINGS INC.
EAT BRINKER INTERNATIONAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
SWKS SKYWORKS SOLUTIONS INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
TMHC TAYLOR MORRISON HOME CORPORATION
HPE HEWLETT PACKARD ENTERPRISE CO.
TWTR TWITTER INC.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
HEAR TURTLE BEACH CORP.
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
BCEL ATRECA
DELL DELL TECHNOLOGIES INC CLASS C
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
LC LENDINGCLUB CORP
SMCI SUPER MICRO COMPUTER
AQST INC.
IDYA AQUESTIVE THERAPEUTICS
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
CRSR ADICET BIO INC
ITOS CORSAIR GAMING
ZNTL ITEOS THERAPEUTICS
PRAX ZENTALIS PHARMACEUTICALS
FUBO PRAXIS PRECISION MEDICINES
TVTX FUBOTV
LSEA TRAVERE THERAPEUTICS INC
VRDN LANDSEA HOMES CORP (A)
DAWN VIRIDIAN THERAPEUTICS INC
ELEV DAY ONE BIOPHARMACEUTICALS INC
OMGA ELEVATION ONCOLOGY
LBPH OMEGA THERAPEUTICS
THRX LONGBOARD PHARMACEUTICALS
MRVL THESEUS PHARMACEUTICALS
STX INC.
DSGN MARVELL TECHNOLOGY INC
ATXS SEAGATE TECHNOLOGY HLDGS PLC
AVTE DESIGN THERAPEUTICS INC
GFS ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX GLOBALFOUNDRIES INC
FUSN RALLYBIO CORP
VIGL KARUNA THERAPEUTICS INC
EWTX FUSION PHARMACEUTICALS INC
VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Liana Moussatos
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.